SCHEMBL752401

SCHEMBL752401

CC(O)(c1ccc(S(=O)(=O)N2CCN(C(=O)C3CC3)CC2)cc1)C(F)(F)F

nearest known ligand 0.62

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 4/20 0.62
PKM P14618 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.59
ALDH1A1 P00352 1/20 0.58
NPSR1 Q6W5P4 1/20 0.55
HSD11B1 P28845 1/20 0.55
GCK P35557 1/20 0.53
GCKR Q14397 1/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
F13A1 P00488 1/20 0.53
TGM2 P21980 1/20 0.53
TGM1 P22735 1/20 0.53
RORC P51449 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL751747 0.86 CNR1 (0.69) CNR1PKML3MBTL1ALDH1A1NPSR1
SCHEMBL734914 0.83 HSD11B1 (0.64) HSD11B1
SCHEMBL734916 0.83 HSD11B1 (0.64) HSD11B1
SCHEMBL752389 0.83 HSD11B1 (0.64) HSD11B1
SCHEMBL734915 0.83 HSD11B1 (0.64) HSD11B1
SCHEMBL752406 0.82 NPC1 (0.64) CNR1PKML3MBTL1ALDH1A1NPSR1
SCHEMBL751867 0.81 ALDH1A1 (0.73) CNR1PKML3MBTL1ALDH1A1NPSR1
SCHEMBL735184 0.81 L3MBTL1 (0.70) CNR1PKML3MBTL1ALDH1A1NPSR1
SCHEMBL752692 0.81 ALDH1A1 (0.75) CNR1PKML3MBTL1ALDH1A1NPSR1
SCHEMBL3556996 0.79 LMNA (0.68) ALDH1A1HSD11B1GCKGCKR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170234881-A1 METHODS OF DIAGNOSING AND TREATING CANCER INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2017-08-17 US disclosed
US-20170234881-A1 METHODS OF DIAGNOSING AND TREATING CANCER INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2017-08-17 US disclosed
US-8138190-B2 Diaza heterocyclic amide compounds and their uses AMGEN INC. (US) 2012-03-20 US disclosed
US-8138190-B2 Diaza heterocyclic amide compounds and their uses AMGEN INC. (US) 2012-03-20 US disclosed
US-20090176768-A1 DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES AMGEN INC. 2009-07-09 US disclosed
US-20090176768-A1 DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES AMGEN INC. 2009-07-09 US disclosed
US-7524848-B2 Diaza heterocyclic amide compounds and their uses AMGEN INC. (US) 2009-04-28 US disclosed
US-7524848-B2 Diaza heterocyclic amide compounds and their uses AMGEN INC. (US) 2009-04-28 US disclosed
US-20070249626-A1 Diaza heterocyclic amide compounds and their uses AMGEN INC. 2007-10-25 US disclosed
US-20070249626-A1 Diaza heterocyclic amide compounds and their uses AMGEN INC. 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176768-A1 DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES GPR119, GLP1R, INSR CNR1 281/4885PKM 1084/4885L3MBTL1 1927/4885
US-20070249626-A1 Diaza heterocyclic amide compounds and their uses GPR119, GLP1R, INSR CNR1 281/4885PKM 1084/4885L3MBTL1 1927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.